Drug Profile
Cetuximab biosimilar - AbbVie/Amgen
Alternative Names: ABP 494Latest Information Update: 24 Mar 2023
Price :
$50
*
At a glance
- Originator Actavis; Amgen
- Developer AbbVie; Amgen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Head and neck cancer
Most Recent Events
- 24 Mar 2023 Discontinued - Preclinical for Colorectal cancer in USA (Parenteral)
- 24 Mar 2023 Discontinued - Preclinical for Head and neck cancer in USA (Parenteral)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)